Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. 1996

M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, England.

The influence of nicotinamide formulation on absorption characteristics and incidence of adverse side-effects has been studied in normal volunteers and in patients undergoing radiotherapy. Escalating single or repeated oral doses of nicotinamide were administered in tablet or liquid form under fasting or non-fasting conditions. Drug absorption was slowed both by the presence of food in the stomach and by the administration of nicotinamide in tablet form compared with when it was dissolved in orange juice. Peak concentrations were generally slightly higher following the liquid preparation, but the incidence of adverse side-effects (chiefly nausea) was increased. A single dose of 9 g (88-97 mg/kg) nicotinamide in tablet form was well tolerated in two fasting normal volunteers, and in patients, doses of up to 133 mg/kg as tablets were tolerated twice/week for three weeks. Daily administration of 80 mg/kg nicotinamide was tolerated when given as tablets, but not in a liquid formulation. Neither the peak concentration nor the area under the concentration/time curve (AUC) of nicotinamide, nor the main metabolites of nicotinamide appeared to correlate with the incidence of toxicity.

UI MeSH Term Description Entries
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
September 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
October 2020, Journal of family medicine and primary care,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
January 1980, Communications in psychopharmacology,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
January 1993, Chemotherapy,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
January 2012, Practical radiation oncology,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
August 1983, The American journal of medicine,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
January 1985, Journal of clinical pharmacology,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
September 1980, The Journal of antimicrobial chemotherapy,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
June 1977, Journal of pharmacokinetics and biopharmaceutics,
M R Stratford, and M F Dennis, and P J Hoskin, and M I Saunders, and R J Hodgkiss, and A Rojas
June 1989, British journal of clinical pharmacology,
Copied contents to your clipboard!